Advances in inherited epidermolysis bullosa

Advances in Dermatology

Volumn 21, Issue , 2005, Pages 303-334

  McAllister, Josephine Chu ^a   Peter Morinkovich, M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29244477589     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2005.07.002     Document Type: Review

References (120)

1. Fine JD, Bauer EA, McGuire J, et al: Epidemiology of inherited epidermolysis bullosa, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, p 112.
2. Pfendner E, Uitto J, Fine JD: Epidermolysis bullosa carrier frequencies in the US population. J Invest Dermatol 116:483-484, 2001.
3. Fine JD, Bauer EA, Gedde-Dahl T: Inherited epidermolysis bullosa: Definition and historical overview, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, pp 1-19.
4. Pai S, Marinkovich MP: Epidermolysis bullosa: New and emerging trends. Am J Clin Dermatol 3:371-380, 2002.
5. Marinkovich MP, Khavari P, Herron S: Inherited epidermolysis bullosa, in Freedberg (ed): Fitzpatrick's Dermatology in General Medicine. San Francisco, McGraw-Hill, 2003, pp 596-608.
6. Porter RM, Lane EB: Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 19:278-285, 2003.
7. Shemanko CS, Horn HM, Keohane SG, et al: Laryngeal involvement in the Dowling-Meara variant of epidermolysis bullosa simplex with keratin mutations of severely disruptive potential. Br J Dermatol 142:315-320, 2000.
8. Morrell DS, Rubenstein DS, Briggaman RA, et al: Congenital pyloric atresia in a newborn with extensive aplasia cutis congenita and epidermolysis bullosa simplex. Br J Dermatol 143:1342-1343, 2000.
9. Lane EB, McLean WH: Keratins and skin disorders. J Pathol 204:355-366, 2003.
10. Sprecher E, Yosipovitch G, Bergman R, et al: Epidermolytic hyperkeratosis and epidermolysis bullosa simplex caused by frameshift mutations altering the v2 tail domains of keratin 1 and keratin 5. J Invest Dermatol 120:623-626, 2003.
11. Chan YM, Yu QC, Fine JD, et al: The genetic basis of Weber-Cockayne epidermolysis bullosa. Proc Natl Acad Sci U S A 90:7414-7418, 1993.
12. Smith FJ, Morley SM, McLean WH: Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. J Invest Dermatol 122:73-77, 2004.
13. Uttam J, Hutton E, Coulombe PA, et al: The genetic basis of epidermolysis bullosa simplex with mottled pigmentation. Proc Natl Acad Sci U S A 93:9079-9084, 1996.
14. Hamada T, Ishii N, Kawano Y, et al: The P25L mutation in the KRT5 gene in a Japanese family with epidermolysis bullosa simplex with mottled pigmentation. Br J Dermatol 150:609-611, 2004.
15. Yasukawa K, Sawamura D, Akiyama M, et al: Keratotic lesions in epidermolysis bullosa simplex with mottled pigmentation. J Am Acad Dermatol 52:172-173, 2005.
16. Gu LH, Kim SC, Ichicki Y, et al: A usual frameshift and delayed termination codon mutation in keratin 5 causes a novel type of epidermolysis bullosa simplex with migratory circinate erythema. J Invest Dermatol 121:482-485, 2003.
17. Nagao-Watanabe M, Fukao T, Matsui E, et al: Identification of somatic and germline mosaicism for a keratin 5 mutation in epidermolysis bullosa simplex in a family of which the proband was previously regarded as a sporadic case. Clin Genet 66:236-238, 2004.
18. Chan Y, Anton-Lamprecht I, Yu QC, et al: A human keratin 14 "knockout": The absence of K14 leads to severe epidermolysis bullosa simplex and a function for an intermediate filament protein. Genes Dev 8:2574-2587, 1994.
19. Indelman M, Bergman R, Sprecher E: A novel recessive missense mutation in KRT14 reveals striking phenotypic heterogeneity in epidermolysis bullosa simplex. J Invest Dermatol 124:272-274, 2005.
20. Lanschuetzer CM, Klausegger A, Pohla-Gubo G, et al: A novel homozygous nonsense deletion/insertion mutation in the keratin 14 gene (Y248X; 744delC/insAG) causes recessive epidermolysis bullosa simplex type Kobner. Clin Exp Dermatol 28:77-79, 2003.
21. Jonkman MF, Heeres K, Pas HH, et al: Effects of keratin 14 ablation on the clinical and cellular phenotype in a kindred with recessive epidermolysis bullosa simplex. J Invest Dermatol 107:764-769, 1996.
22. Jonkman MF, Pas HH, Nijenhuis M, et al: Deletion of a cytoplasmic domain of integrin beta4 causes epidermolysis bullosa simplex. J Invest Dermatol 119:1275-1281, 2002.
23. Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, et al: A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: Two identical de novo mutations. J Invest Dermatol 118:87-93, 2002.
24. Meneguzzi G, Marinkovich MP, Aberdam D, et al: Kalinin is abnormally expressed in epithelial basement membranes of Herlitz's junctional epidermolysis bullosa patients. Exp Dermatol 1:221-229, 1992.
25. McGrath JA, Gatalica B, Christiano AM, et al: Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 11:83-86, 1995.
26. Davies H, Atherton DJ: Acute laryngeal obstruction in junctional epidermolysis bullosa. Pediatr Dermatol 4:98-101, 1987.
27. Kivirikko S, McGrath JA, Baudoin C, et al: A homozygous nonsense mutation in the alpha 3 chain gene of laminin 5 (LAMA3) in lethal (Herlitz) junctional epidermolysis bullosa. Hum Mol Genet 4:959-962, 1995.
28. Pulkkinen L, Christiano AM, Gerecke D, et al: A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa. Genomics 24:357-360, 1994.
29. Aberdam D, Galliano MF, Vailly J, et al: Herlitz's junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the gamma 2 subunit of nicein/kalinin (LAMININ-5). Nat Genet 6:299-304, 1994.
30. Posteraro P, DeLuca N, Meneguzzi G, et al: Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa. J Invest Dermatol 123:639-648, 2004.
31. Pulkkinen L, Meneguzzi G, McGrath JA, et al: Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J Invest Dermatol 109:232-237, 1997.
32. Muhle C, Jiang QJ, Charlesworth A, et al: Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: Molecular basis and clinical course of Herlitz disease. Hum Genet 116:33-42, 2005.
33. Cserhalmi-Friedman PB, Anyane-Yeboa K, Christiano AM: Paternal germline mosaicism in Herlitz junctional epidermolysis bullosa. Exp Dermatol 11:468-470, 2002.
34. Matsui C, Pereira P, Wang CK, et al: Extent of laminin-5 assembly and secretion effect junctional epidermolysis bullosa phenotype. J Exp Med 187:1273-1283, 1998.
35. Fox AT, Alderdice F, Atherton DJ: Are children with recessive dystrophic epidermolysis bullosa of low birthweight? Pediatr Dermatol 20:303-306, 2003.
36. Jarvikallio A, Pulkkinen L, Uitto J: Molecular basis of dystrophic epidermolysis bullosa: Mutations in the type VII collagen gene (COL7A1). Hum Mutat 10:338-347, 1997.
37. Ryynanen M, Knowlton RG, Parente MG, et al: Human type VII collagen: Genetic linkage of the gene (COL7A1) on chromosome 3 to dominant dystrophic epidermolysis bullosa. Am J Hum Genet 49:797-803, 1991.
38. Uitto J, Christiano AM: Molecular basis for the dystrophic forms of epidermolysis bullosa: Mutations in the type VII collagen gene. Arch Dermatol Res 287:16-22, 1994.
39. Christiano AM, Ryynanen M, Uitto J: Dominant dystrophic epidermolysis bullosa: Identification of a Gly→Ser substitution in the triple-helical domain of type VII collagen. Proc Natl Acad Sci U S A 91:3549-3553, 1994.
40. Murata T, Masunaga T, Shimizu H, et al: Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 292:477-481, 2000.
41. Nakamura H, Sawamura D, Goto M, et al: The G2028R glycine substitution mutation in COL7A1 leads to marked inter-familiar clinical heterogeneity in dominant dystrophic epidermolysis bullosa. J Dermatol Sci 34:195-200, 2004.
42. Chuang GS, Martinez-Mir A, Yu HS, et al: A novel missense mutation in the COL7A1 gene underlies epidermolysis bullosa pruriginosa. Clin Exp Dermatol 29:304-307, 2004.
43. Mellerio JE, Ashton GH, Mohammedi R, et al: Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol 112:984-987, 1999.
44. Fine JD, Bauer EA, McGuire J, et al: Molecular basis of the dystrophic forms of epidermolysis bullosa, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, p 338.
45. Gardella R, Zoppi N, Zambruno G, et al: Different phenotypes in recessive dystrophic epidermolysis bullosa patients sharing the same mutation in compound heterozygosity with two novel mutations in the type VII collagen gene. Br J Dermatol 147:450-457, 2002.
46. Sato-Matsumura KC, Sawamura D, Goto M, et al: A novel insertion mutation in COL7A1 identified in Hallopeau-Siemens recessive dystrophic epidermolysis bullosa. Acta Derm Venereol 83:137-138, 2003.
47. Ishiko A, Masunaga T, Ota T, et al: Does the position of the premature termination codon in COL7A1 correlate with the clinical severity in recessive dystrophic epidermolysis bullosa? Exp Dermatol 13:229-233, 2004.
48. Horev L, Waran Lalin T, Martinez-Mir A, et al: Identification of mutations in the COL7A1 gene in a proband with mild recessive dystrophic epidermolysis bullosa and aortic insufficiency. Clin Exp Dermatol 28:80-84, 2003.
49. Chavanas S, Pulkkinen L, Gache Y, et al: A homozygous nonsense mutation in the PLEC1 gene in patients with epidermolysis bullosa simplex with muscular dystrophy. J Clin Invest 98:2196-2200, 1996.
50. McLean WH, Pulkkinen L, Smith FJ, et al: Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. Genes Dev 10:1724-1735, 1996.
51. Smith FJ, Eady RA, Leigh IM, et al: Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet 13:450-457, 1996.
52. Schara U, Tucke J, Mortier W, et al: Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. Eur J Pediatr 163:218-222, 2004.
53. Koss-Harnes D, Hoyheim B, Jonkman MF, et al: Life-long course and molecular characterization of the original Dutch family with epidermolysis bullosa simplex with muscular dystrophy due to a homozygous novel plectin point mutation. Acta Derm Venereol 84:124-131, 2004.
54. Charlesworth A, Gagnoux-Palacios L, Bonduelle M, et al: Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. J Invest Dermatol 121:1344-1348, 2003.
55. Koster J, Kuikman I, Kreft M, et al: Two different mutations in the cytoplasmic domain of the integrin beta 4 subunit in nonlethal forms of epidermolysis bullosa prevent interaction of beta 4 with plectin. J Invest Dermatol 117:1405-1411, 2001.
56. Jonkman FM, de Jong MC, Heeres K, et al: 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J Clin Invest 95:1345-1352, 1995.
57. Baur JW, Lanschuetzer C: Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin Exp Dermatol 28:53-60, 2003.
58. Whittick NV, Sher C, Gold I, et al: A founder COL17A1 splice site mutation leading to generalized atrophic benign epidermolysis bullosa in an extended inbred Palestinian family from Israel. Genet Med 5:435-439, 2003.
59. Pasmooij AM, van Zalen S, Nijenhuis AM, et al: A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by outsplicing of mutated exon 30 coding for the COL15 domain. Exp Dermatol 13:125-128, 2004.
60. McGrath JA, Pulkkinen L, Christiano AM, et al: Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 104:467-474, 1995.
61. Jonkman MF, Pas HH, Fine JD: Mosaic expression of uncein, linear IgA bullous dermatosis antigen and 180-kDa bullous pemphigoid antigen in generalized atrophic benign epidermolysis bullosa. Br J Dermatol 138:904, 1998.
62. Fontao L, Tasanen K, Huber M, et al: Molecular consequences of deletion of the cytoplasmic domain of bullous pemphigoid 180 in a patient with predominant features of epidermolysis bullosa simplex. J Invest Dermatol 122:65-72, 2004.
63. Gil SG, Brown TA, Ryan MC, et al: Junctional epidermolysis bullosis: Defects in expression of epiligrin/nicein/kalinin and integrin beta 4 that inhibit hemidesmosome formation. J Invest Dermatol 103:31S-38S, 1994.
64. Vidal F, Aberdam D, Miquel C, et al: Integrin beta 4 mutations associated with junctional epidermolysis bullosa with pyloric atresia. Nat Genet 10:229-234, 1995.
65. Masunaga T, Ishiko A, Takizawa Y, et al: Pyloric atresia-junctional epidermolysis bullosa syndrome showing novel 594insC/Q425P mutations in integrin beta4 gene (ITGB4). Exp Dermatol 13:61-64, 2004.
66. Ruzzi L, Gagnoux-Palacios L, Pinola M, et al: A homozygous mutation in the integrin alpha 6 gene in junctional epidermolysis bullosa with pyloric atresia. J Clin Invest 99:2826-2831, 1997.
67. Georges Labouesse E, Messaddeq N, Yehia G, et al: Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. Nat Genet 13:370-373, 1996.
68. van der Neut R, Krimpenfort P, Calafat J, et al: Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice. Nat Genet 13:366-369, 1996.
69. Iacovacci S, Cicuzza S, Odorisio T, et al: Novel and recurrent mutations in the integrin beta 4 subunit gene causing lethal junctional epidermolysis bullosa with pyloric atresia. Exp Dermatol 12:716-720, 2003.
70. Micheloni A, De Luca N, Tadini G, et al: Intracellular degradation of beta 4 integrin in lethal junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol 151:796-802, 2004.
71. Allegra M, Gagnoux-Palacios M, Gache Y, et al: Rapid decay of alpha 6 integrin caused by a mis-sense mutation in the propeller domain results in severe junctional epidermolysis bullosa with pyloric atresia. J Invest Dermatol 121:1336-1343, 2003.
72. Petronius D, Bergman R, Ben Izhak O, et al: A comparative study of immunohistochemistry and electron microscopy used in the diagnosis of epidermolysis bullosa. Am J Dermatopathol 25:198-203, 2003.
73. Pfendner EG, Nakano A, Pulkkinen L, et al: Prenatal diagnosis for epidermolysis bullosa: A study of 144 consecutive pregnancies at risk. Prenat Diagn 23:447-456, 2003.
74. Cserhalmi-Friedman PB, Tang Y, Adler A, et al: Preimplantation genetic diagnosis in two families at risk for recurrence of Herlitz junctional epidermolysis bullosa. Exp Dermatol 9:290-297, 2000.
75. Gannon BA: Epidermolysis bullosa: Pathophysiology and nursing care. Neonatal Netw 23:25-32, 2004.
76. Nopper AJ, Horii KA, Sookdeo-Drost S, et al: Topical ointment therapy benefits premature infants. J Pediatr 128:660-669, 1996.
77. Banky JP, Sheridan AT, Storer EL, et al: Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol 140:794-796, 2004.
78. Ozerdem OR, Wolfe SA, Marshall D: Use of skin substitutes in pediatric patients. J Craniofac Surg 14:517-520, 2003.
79. Hasegawa T, Suga Y, Mizoguchi M, et al: Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 50:803-804, 2004.
80. Ingen-Housz-Oro S, Blanchet-Bardon C, Vrillat M, et al: Vitamin and trace metal levels in recessive dystrophic epidermolysis bullosa. J Eur Acad Dermatol Venereol 18:649-653, 2004.
81. Birge K: Nutrition management of patients with epidermolysis bullosa. J Am Diet Assoc 95:575-579, 1995.
82. Reyes ML, Cattani A, Gajardo H, et al: Bone metabolism in children with epidermolysis bullosa. J Pediatr 140:467-469, 2002.
83. Kawaguchi M, Mitsuhashi Y, Kondo S: Osteoporosis in a patient with recessive dystrophic epidermolysis bullosa. Br J Dermatol 141:934-935, 1999.
84. Atherton DJ, Cox I, Hann I: Intravenous iron (III) hydroxide-sucrose complex for anaemia in epidermolysis bullosa. Br J Dermatol 140:773, 1999.
85. Fridge JL, Vichinsky EP: Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. J Pediatr 132:871-873, 1998.
86. Iohom G, Lyons B: Anaesthesia for children with epidermolysis bullosa: A review of 20 years' experience. Eur J Anaesthesiol 18:745-754, 2001.
87. Fine JD, Johnson LB, Weiner M, et al: Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: Experience of the National Epidermolysis Bullosa Registry, 1986-2002. J Hand Surg 30:14-22, 2005.
88. Fivenson DP, Scherschun L, Cohen LV: Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg 112:584-588, 2003.
89. Shirakata Y, Tamai K, Nakaoka H, et al: Severe palmo-plantar hyperkeratosis in Koebner epidermolysis bullosa simplex. J Dermatol 30:135-140, 2003.
90. Mallipeddi R, Keane FM, McGrath JA, et al: Increased risk of squamous cell carcinoma in junctional epidermolysis bullosa. J Eur Acad Dermatol Venereol 18:521-526, 2004.
91. Yamada M, Hatta N, Sogo K, et al: Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica. Dermatol Surg 30:1424-1429, 2004.
92. Fine JD: Possible role for sentinal node biopsy in the management of squamous cell carcinomas in inherited epidermolysis bullosa. Arch Dermatol 140:1012-1013, 2004.
93. Fine JD, Johnson LB, Weiner M, et al: Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: Results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 50:563-571, 2004.
94. Wong WL, Entwisle K, Pemberton J: Gastrointestinal manifestations in the Hallopeau-Siemens variant of recessive dystrophic epidermolysis bullosa. Br J Radiol 66:788-793, 1993.
95. Anderson SH, Meenan J, Williams KN, et al: Efficacy and safety of endoscopic dilation of esophageal strictures in epidermolysis bullosa. Gastrointest Endosc 59:28-32, 2004.
96. Castillo RO, Davies YK, Lin YC, et al: Management of esophageal strictures in children with recessive dystrophic epidermolysis bullosa. J Pediatr Gastroenterol Nutr 34:535-541, 2002.
97. Fine JD, Johnson LB, Weiner M, et al: Eye involvement in inherited epidermolysis bullosa: Experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol 138:254-262, 2004.
98. De Benedittis M, Petruzzi M, Favia G, et al: Oro-dental manifestations in Hallopeau-Siemens-type recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 29:128-132, 2004.
99. Marini I, Vecchiet F: Sucralfate: A help during oral management in patients with epidermolysis bullosa. J Periodontol 72:691-695, 2001.
100. Fine JD, Bauer EA, McGuire J, et al: Oral manifestations of epidermolysis bullosa, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, p 252.
101. Buduneli E, Ilgenli T, Buduneli N, et al: Acellular dermal matrix allograft used to gain attached gingiva in a case of epidermolysis bullosa. J Clin Periodontol 30:1011-1015, 2003.
102. Kaneko K, Kakuta M, Ohtomo Y, et al: Renal amyloidosis in recessive dystrophic epidermolysis bullosa. Dermatology 200:209-212, 2000.
103. Fine JD, Johnson JB, Weiner M, et al: Genitourinary complications of inherited epidermolysis bullosa: Experience of the National Epidermylosis Bullosa Registry and review of the literature. J Urol 172:2040-2044, 2004.
104. Weiner M, Stein A, Cash S, et al: Tetracycline and epidermolysis bullosa simplex: A double-blind, placebo-controlled, crossover randomized clinical trial. Br J Dermatol 150:613-614, 2004.
105. Kaneko K, Someya T, Ohtaki R, et al: Colchicine therapy in amyloid nephropathy due to recessive dystrophic epidermolysis bullosa. Pediatr Nephrol 18:1311-1312, 2003.
106. Hengge UR, Bardenheuer W: Gene therapy and the skin. Am J Med Genet 131C:93-100, 2004.
107. Coberly SBM, Tran HT, Keene DR, et al: Exogenous laminin 5 protein therapy corrects JEB keratinocyte adhesive defects in vitro and basement membrane defects in a JEB skin equivalent system. J Invest Dermatol 108:549A, 1997.
108. Woodley DT, Keene DR, Atha T, et al: Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10:693-695, 2004.
109. Vailly J, Gagnoux-Palacios L, Dell'Ambra E, et al: Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther 5:1322-1332, 1998.
110. Seitz CS, Giudice GJ, Balding SD, et al: BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther 6:42-47, 1999.
111. Dellambra E, Vailly J, Pellegrini G, et al: Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum Gene Ther 9:1359-1370, 1998.
112. Robbins PB, Lin Q, Goodnough JB, et al: In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A 98:5193-5198, 2001.
113. Chen M, Kasahara N, Keene DR, et al: Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32:670-675, 2002.
114. Ortiz-Urda S, Thyagarajan B, Keene DR, et al: Stable nonviral genetic correction of inherited human skin disease. Nat Med 8:1166-1170, 2002.
115. Ortiz-Urda S, Lin Q, Yant SR, et al: Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 10:1099-1104, 2003.
116. Ortiz-Urda S, Lin Q, Green CL, et al: Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 111:251-255, 2003.
117. Woodley DT, Krueger GG, Jorgensen CM, et al: Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121:1021-1028, 2003.
118. Woodley DT, Keene DR, Atha T, et al: Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10:318-326, 2004.
119. Fine JD, Johnson LB, Suchindran C, et al: Extracutaneous manifestations of inherited epidermolysis bullosa, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, pp 147-174.
120. Fine JD, Johnson LB, Moshell A, et al: The risk of selected major extracutaneous outcomes in inherited epidermolysis bullosa, in Fine JD (ed): Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore, Md, Johns Hopkins University Press, 1999, pp 193-205.